Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raptiva in Sjogren's Syndrome
NCT00344448Phase 2Terminated
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Jun 2006
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of efalizumab in Sjogren's syndrome, sponsored by National Institute of Dental and Craniofacial Research. Started Jun 2006; status: terminated.
02
Drugs
efalizumab
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT00344448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00344448.